Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use

PURPOSE: Cetuximab, which modulates immune responses, may affect the efficacy of subsequent immunotherapy. Here, we assessed outcomes with nivolumab, by prior cetuximab exposure, in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) who had experienced p...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Ferris, Robert L., Licitra, Lisa, Fayette, Jerome, Even, Caroline, Blumenschein, George, Harrington, Kevin J., Guigay, Joel, Vokes, Everett E., Saba, Nabil F., Haddad, Robert, Ramkumar, Shanmugasundaram, Russell, Jeffery, Brossart, Peter, Tahara, Makoto, Colevas, A. Dimitrios, Concha-Benavente, Fernando, Lynch, Mark, Li, Li, Gillison, Maura L.
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7721346/
https://ncbi.nlm.nih.gov/pubmed/31239321
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-3944
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados